As of November 6, 2026, STERIS plc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 7, 2026 to August 6, 2026, naming 2 appointments and 1 departure. The latest filing names Pierre Boulud, appointed (Form 8-K, August 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like STERIS plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
STERIS plc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-07 to 2026-08-06. They name 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as STERIS plc files it.
Layoffs on record: 1 filing or notice, latest 2026-08-05 (layoff filings and notices).
Also on the record for STERIS plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.1% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.48% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.05% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 4, 2025 | Stake report, Schedule 13G/A, by Massachusetts Financial Services Company | 4.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs STERIS plc now and the warning signs.
Free to see. No signup.
Keep reading
More on STERIS plc and the records around it.
STERIS plc elsewhere on the record
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- Massachusetts Financial Services Company also filed stake reports on 26 other companies: ASHLAND INC. (Aug 2026), BLACKSTONE DIGITAL INFRASTRUCTURE TRUST INC (Aug 2026), PG&E CORP (Aug 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
Watch STERIS plc
Get an email when STERIS plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on STERIS plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on STERIS plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on STERIS plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-06 | In | 8-K/A, 2026-08-06 | |||
| 2026-05-07 | Out | 8-K, 2026-05-07 | |||
| 2026-05-07 | In | Director | 8-K, 2026-05-07 |
Who leads STERIS plc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Pierre Boulud, appointed (filed 2026-05-07).
New leaders reset buying decisions — get the Full Report on STERIS plc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at STERIS plc, with the record behind each one.
Find candidates like Director at STERIS plcEvery change, in the filing's words
Appointed: Pierre Boulud
The Original Form 8-K reported that the Board of Directors of the Company (the "Board") increased its size from nine to ten members on May 5, 2026, and elected Pierre Boulud to serve as a Director effective as of that date.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- On July 31, 2026, Pierre Boulud was appointed to serve on the Audit Committee of the Board and the Compliance and Technology Committee of the Board.
Departing: Richard C. Breeden
On May 1, 2026, Richard C. Breeden notified STERIS plc (the "Company") that he will not stand for reelection to the Board of Directors (the "Board") at the Company's 2026 Annual General Meeting of Shareholders.
Appointed: Pierre Boulud, Director
On May 5, 2026, the Board of the Company increased its size from nine to ten members and appointed Pierre Boulud to serve as a director effective as of that date.
- Mr. Breeden's decision to retire is not the result of any disagreement with the Company on any matters related to the Company's operations, policies or practices.
- The Company and the Board thank Mr. Breeden for his 18 years of service to the Company as a Director.
- Mr. Boulud, age 54, is the Chief Executive Officer of bioM rieux, a biotechnology company focused on in vitro diagnostics, having served in that role since June 2023.
- Mr. Boulud joined bioM rieux in 2016 as Corporate Vice President, Head of Asia Pacific Region, and was promoted to Chief Operating Officer in 2020.
- Previously, he worked at Ipsen, a pharmaceutical company, from 2002 until 2016, serving in various roles of increasing responsibility and ultimately as the Executive Vice President of Specialty Care Commercial Operations.
- Mr. Boulud began his career as a strategic consultant, working at Bossard Consultants from 1995 to 1997 and at the Boston Consulting Group from 1997 to 2002.
- Mr. Boulud will receive a prorated fee of $76,989 for the remainder of the Board's 2025-26 term of office, which will be payable in career restricted stock units granted in conjunction with the Company's Non-Employee Director Compensation Program.
- Mr. Boulud will be eligible for the same indemnification program as the other members of the Board.
Tools for this story
Each opens in a new tab, filled in for STERIS plc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.